Qiagen Marseille424364412

Recherche-développement en biotechnologie

3 avenue du Canada (ZA de Courtaboeuf Parc Technopolis) 91940 Les Ulis

Indice de confiance

Laissez un avis

Chiffre d'affaires 2015

3 M€

Président

Thierry

Bernard

Effectif 2020

3 à 5

Ancienneté

21 ans

Indicateurs

À propos

QIAGEN is the leading provider of sample to insight solutions.
Making improvements in life possible.Source : Facebook

#QIAGEN is a leading provider of molecular Sample to Insight solutions. Impressum: https://t.co/hANYkswUlgSource : Twitter

Making improvements in life possible. #SampleToInsight
#QIAGEN
🧬🧪🧫🔬New Story on QIAGEN.com ⬇️Source : Instagram

QIAGEN's position as the market leader for sample and assay technologies is based on more than 25 years of experience, strong relationships with customers, our spirit of innovation, and a passion for quality. Quality is what our customers can expect from QIAGEN today and in the future — quality in product and service performance, reliable results and applications, consistency and reproducibility of research data, as well as excellent ease-of-use.

Today, QIAGEN is present in more than 35 locations worldwide and supports over 500,000 customers to achieve successes and breakthroughs in areas of scientific research, in diagnostics laboratories, and in the pharmaceutical and biotech industries. Consequently, QIAGEN makes a significant contribution to the global application of science to real-life problems — making improvements in life possible.Source : Youtube

Recherche développement commercialisation dans le domaine biotechnologies et commercialisation de logiciels dans le domaine des biotechnologiesSource : BODACC

La structure Qiagen Marseille a un indice de confiance de 95 sur 100, cet indice est établi grâce à de nombreux paramètres. Les dernières marques déposées de cette dernière sont MUTASEARCH, MUTAQUANT et FusionQuant, elle dispose de 19 marques déposées à son actif. Elle disposait d' un capital social de 1089116.6 euros pendant l'année 2016. Le numéro de TVA correspondant à l'activité de Qiagen Marseille est : FR64424364412. Il y avait 3 à 5 salariés qui travaillaient pour cette dernière au cours de l'année 2020. Cette dernière exerce dans la recherche-développement en biotechnologie, le code NAF lié est 7211Z. L'entreprise Qiagen Marseille a domiciliée son établissement principal à Les Ulis. Son Président actuel est Thierry Bernard. Elle a été créée en 1999. L'entreprise Qiagen Marseille dispose de 3 certifications tel que, ISO 50001, ISO 9001 et ISO 13485. Elle détient le numéro de SIREN suivant : 424364412. Cette société est relativement présente sur différents réseaux sociaux notamment Facebook puis Twitter. Vous pouvez retrouver la page Facebook de cette entreprise sous le nom de qiagen et sur Twitter sous le nom de qiagen. Une société plutôt active sur les réseaux, elle possède 13649 followers sur son compte Twitter puis 46643 likes sur sa page Facebook.

Fiche d'identité

  1. Type Société par actions simplifiée (SAS)
  2. Date de création 23/09/1999
  3. Effectif 3 à 5 (2020)
  4. Capital social 1089116.6€ (2016) (Source RCS)
  5. Chiffre d'affaires 3 M€ (2015)
  6. TVA intercommunautaire FR64424364412
  7. Numéro de SIREN 424364412
  8. Code NAF Recherche-développement en biotechnologie (7211Z)
  9. Statut SIRENE Active
  10. Statut RCS Immatriculée (05/09/2016)

Contacts

Site web

Site internet de Qiagen Marseille

Réseaux sociaux

Téléphones

{[{phoneItem.phone}]}

+334********

+338********

Email

{[{emailItem.email}]}

****@****en.com

Obtenez des millions de téléphones et emails nominatifs.

En savoir plus

Il s’agit de votre entreprise ?

Mettez en valeur votre activité en complétant les informations de cette page et invitez vos partenaires à vous évaluer pour construire votre e-réputation.

Revendiquez votre page gratuitement !

Avis Qiagen Marseille (0)

Que pensez-vous de Qiagen Marseille ?

Actuellement aucun avis publié, soyez le premier !

Laisser un avis

Dirigeants Qiagen Marseille (7)

Âge moyen des dirigeants

54 ANS

Durée moyenne de mandat

1 MOIS

Parité

0%100%
  • Thierry Bernard

    Président

    2020 - Présent

    En poste
  • Roland Sackers

    Directeur général

    2020 - Présent

    En poste
  • Christian Davoult

    Commissaire aux comptes titulaire

    2016 - Présent

    En poste
  • Grant Thornton

    Commissaire aux comptes titulaire

    2016 - Présent

    En poste
  • Antoine Olanda

    Commissaire aux comptes suppléant

    2016 - Présent

    En poste
  • Institut Gest Expert Comptable

    Commissaire aux comptes suppléant

    2016 - Présent

    En poste
  • Peer Schatz

    Président

    2016 - 2020

    Ancien

    ***********@****en.com PRO

    {[{ company.directors.identities[6].email }]}

Employés Qiagen Marseille (4)

  • Arnaud B.

    Technical Services Director South Europe and EMEA Commercial Partners

    **************@****en.com PRO

  • Sylvie M.

    Head of Tenders and Contracts Office EMEA

    ***************@****en.com PRO

  • Vous voulez voir tous les employés ?

    Obtenez dès maintenant les mails nominatifs des employés clés

Chiffre d'affaires, bilans Qiagen Marseille (3)

Durée de l'exercice comptable : 12 mois

Chiffre d'affaires

0

Résultat net

9,4 M€

14 %

Capacité d'autofinancement

11,8 M€

15 %

Vous voulez le détail des comptes ?

Inscivez-vous et téléchargez le bilan et le compte de résultat des comptes sociaux déposés en 2018 par Qiagen Marseille

Télécharger les comptes

Chiffres clés

Chiffre d'affaires

0

Résultat net

9,4 M€

14 %

Capacité d'autofinancement

11,8 M€

15 %

Taille du bilan

59,3 M€

14,8 %

Fonds propres

57,9 M€

19,3 %

Trésorerie nette

0

100 %

Ratios financiers

Rendement des fonds propres

22,9 %

0,8 %

L'entreprise affiche des fonds propres et un résultat courant positifs.

Equilibre financier

296,3 %

Autonomie financière

97,8 %

3,9 %

La structure financière est excellente en termes de capitalisation.

Liquidité générale

33,1

189,4 %

Délai moyen fournisseurs

2 033 jours

126,4 %

Cette entreprise règle en moyenne ses fournisseurs à 2 033 jours, ce qui est très largement plus que les seuils prévus par la loi LME.

Score financier

PRO

Accédez au score financier

Vérifiez et anticipez le risque de défaillance de vos clients, fournisseurs et partenaires.

En savoir plus

Liens capitalistiques

PRO

Accédez aux liens capitalistiques

Découvrez la structure du groupe auquel appartient cette entreprise : tête de groupe, actionnaire majoritaire et filiales.

En savoir plus

Annonces légales (47)

  • Modification

    29 oct. 2020

    QIAGEN Marseille a apporté une modification à ses dirigeants ou son administration, qui se compose désormais comme telle :
    Président : BERNARD Thierry, Laurent ; Directeur général : SACKERS Roland ; Commissaire aux comptes titulaire : GRANT THORNTON ; Commissaire aux comptes titulaire : DAVOULT Christian ; Commissaire aux comptes suppléant : INSTITUT DE GESTION ET D'EXPERTISE COMPTABLE - IGEC ; Commissaire aux comptes suppléant : OLANDA Antoine.

  • Modification

    6 oct. 2020

    QIAGEN Marseille a apporté une modification à ses dirigeants ou son administration, qui se compose désormais comme telle :
    Président : BERNARD Thierry, Laurent  Commissaire aux comptes titulaire : GRANT THORNTON  Commissaire aux comptes titulaire : DAVOULT Christian  Commissaire aux comptes suppléant : INSTITUT DE GESTION ET D'EXPERTISE COMPTABLE - IGEC  Commissaire aux comptes suppléant : OLANDA Antoine.

  • Dépôt des comptes

    18 juil. 2019

    L'entreprise a déposé ses comptes annuels et rapports (arrêtés au 31/12/2018).

  • Dépôt des comptes

    18 déc. 2018

    L'entreprise a déposé ses comptes annuels et rapports (arrêtés au 31/12/2017).

  • Dépôt des comptes

    31 août 2017

    L'entreprise a déposé ses comptes annuels et rapports (arrêtés au 31/12/2016).

  • Immatriculation

    8 sept. 2016

    QIAGEN Marseille a procédé à une nouvelle immatriculation suite au transfert de son siège social depuis le ressort d'un autre tribunal. Le nouveau siège est.

  • Modification

    26 août 2016

    QIAGEN Marseille a changé sa forme juridique de Société anonyme en Société par actions simplifiée. QIAGEN Marseille a apporté une modification à ses dirigeants ou son administration, qui se compose désormais comme telle :
    Commissaire aux comptes suppléant : OLANDA Antoine en fonction le 27 Février 2008 Commissaire aux comptes titulaire : DAVOULT Christian modification le 26 Juin 2014 Président : SCHATZ Peer modification le 23 Août 2016 Commissaire aux comptes suppléant : INSTITUT DE GESTION ET D'EXPERTISE COMPTABLE - IGEC en fonction le 26 Juin 2014 Commissaire aux comptes titulaire : GRANT THORNTON en fonction le 26 Juin 2014.

  • Dépôt des comptes

    17 août 2016

    L'entreprise a déposé ses comptes annuels et rapports (arrêtés au 31/12/2015).

  • Modification

    10 mai 2015

    QIAGEN Marseille a apporté une modification à ses dirigeants ou son administration, qui se compose désormais comme telle :
    Commissaire aux comptes suppléant : OLANDA Antoine en fonction le 27 Février 2008 Commissaire aux comptes titulaire : DAVOULT Christian modification le 26 Juin 2014 Administrateur : CONNAN Guillaume en fonction le 10 Mai 2010 Administrateur : VON HUGO Philipp en fonction le 09 Août 2011 Administrateur : SACKERS Roland en fonction le 09 Août 2011 Président du conseil d'administration Directeur général : SCHATZ Peer modification le 29 Avril 2015 Commissaire aux comptes suppléant : INSTITUT DE GESTION ET D'EXPERTISE COMPTABLE - IGEC en fonction le 26 Juin 2014 Commissaire aux comptes titulaire : GRANT THORNTON en fonction le 26 Juin 2014 Administrateur : NEIDERT Thomas en fonction le 15 Avril 2015 Administrateur : POTGETER Martin en fonction le 15 Avril 2015.

  • Modification

    23 avr. 2015

    QIAGEN Marseille a apporté une modification à ses dirigeants ou son administration, qui se compose désormais comme telle :
    Directeur général : FERT Vincent modification le 15 Avril 2015 Commissaire aux comptes suppléant : OLANDA Antoine en fonction le 27 Février 2008 Commissaire aux comptes titulaire : DAVOULT Christian modification le 26 Juin 2014 Administrateur : CONNAN Guillaume en fonction le 10 Mai 2010 Administrateur : VON HUGO Philipp en fonction le 09 Août 2011 Administrateur : SACKERS Roland en fonction le 09 Août 2011 Président du conseil d'administration : SCHATZ Peer en fonction le 09 Août 2011 Commissaire aux comptes suppléant : INSTITUT DE GESTION ET D'EXPERTISE COMPTABLE - IGEC en fonction le 26 Juin 2014 Commissaire aux comptes titulaire : GRANT THORNTON en fonction le 26 Juin 2014.

  • Vous voulez voir toutes les annonces légales ?

    Créez un compte pour accéder à l'ensemble des données sur cette entreprise.

Marques déposées (19)

  • MUTASEARCH

    23 juil. 2009

    23 juil. 2029

    Marque renouvelée

    MUTAQUANT

    15 févr. 2008

    15 févr. 2028

    Marque renouvelée

    FusionQuant

    14 nov. 2002

    14 nov. 2022

    Marque renouvelée

    Ipso gen CancerProfiler

    28 mai 2002

    28 mai 2022

    Marque renouvelée

  • PROFILEQUANT

    28 mai 2002

    28 mai 2022

    Marque renouvelée

    IPSOGEN

    4 févr. 2002

    4 févr. 2022

    Marque renouvelée

    GENEFINDER

    1 août 2001

    1 août 2021

    Marque renouvelée

    MAPQUANT DX

    26 mai 2008

    26 mai 2018

    Marque expirée

  • IPSOGEN CANCER PROFILER

    26 mai 2008

    26 mai 2018

    Marque expirée

    FusionChip

    14 nov. 2002

    14 nov. 2012

    Marque expirée

    IDGRAPHER

    28 mai 2002

    28 mai 2012

    Marque expirée

    PROFILESOFTWARE

    28 mai 2002

    28 mai 2012

    Marque expirée

  • PROFILECHIP

    28 mai 2002

    28 mai 2012

    Marque expirée

    IPSOGEN THE BIOCHIP DESIGN COMPANY

    1 août 2001

    1 août 2011

    Marque expirée

    MICROARRAY FACILITY

    1 août 2001

    1 août 2011

    Marque expirée

    CLONECHOOSER

    1 août 2001

    1 août 2011

    Marque expirée

  • ELOGE

    1 août 2001

    1 août 2011

    Marque expirée

    GENPATH

    1 août 2001

    1 août 2011

    Marque expirée

    GENLAB

    1 août 2001

    Demande totalement rejetée

Répartition par classe des marques

Classe principale

La catégorie la plus utilisée est la classe 05, à savoir "Produits pharmaceutiques et médicaux, produits vétérinaires".

ClassesNb de marques
05 7
10 6
09 5
44 1

Adresse Qiagen Marseille (1)

  • Siret : 42436441200058 (siège social)

    Actif

    3 avenue du Canada (ZA de Courtaboeuf Parc Technopolis) 91940 Les Ulis

    Recherche-développement en biotechnologie (7211Z)

    1 août 2016

    0

    Siret : 42436441200041

    Fermé

    163 avenue de Luminy (Luminy Biotech Case 923) 13009 Marseille

    Recherche-développement en biotechnologie (7211Z)

    1 avr. 2004

    1 août 2016

  • Siret : 42436441200033

    Fermé

    2 boulevard Luce (Bat a) 13008 Marseille

    22 juil. 2002

    1 avr. 2004

    Siret : 42436441200025

    Fermé

    232 boulevard de Sainte Marguerite 13009 Marseille

    Recherche-développement en biotechnologie (7211Z)

    4 sept. 2001

    24 juin 2016

  • Siret : 42436441200017

    Fermé

    163 avenue de Luminy (Bt Ccimp Case 915) 13009 Marseille

    23 sept. 1999

    31 déc. 2001

Certifications (3)

Trafic du site web

Accédez aux statistiques du site web

Évaluez l'empreinte digitale de cette entreprise et son évolution grâce aux statistiques sur son trafic mensuel, ses sources du trafic, le temps passé par les internautes, etc.

En savoir plus

Réseaux sociaux Qiagen Marseille (4)

Vidéos Qiagen Marseille (50)

  • QIAstat-Dx - Dr. Utsav Pandey discusses the importance of syndromic testing for respiratory diseases

    11 nov. 2019

    Treating respiratory disease without a proper diagnosis can result in unnecessary prescribing of antibiotics, one of the driving forces for multidrug resistance in bacteria. Dr. Utsav Pandey discusses the importance of syndromic testing to obtain an accurate diagnosis and treatment. Learn more about syndromic testing with the QIAstat-Dx: https://qiastat-dx.com/ Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Interview on syndromic testing with Glen Hansen at ESCV 2019 in Copenhagen

    13 sept. 2019

    Glen Hansen, Director of Clinical Microbiology and Molecular Diagnostics, Hennepin County Medical Center, speaks about the value of syndromic testing at the point of care and its impact in the hospital.

  • ESCV 2019 - Dr. George Sourvinos speaks about comparing syndromic testing technologies

    20 sept. 2019

    Dr. George Sourvinos of the University Hospital of Crete speaks at ESCV in Copenhagen about the potential for syndromic testing with respiratory infections and a recent comparison study evaluating the QIAstat-Dx. Go to: https://qiastat-dx.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Sajid Javed at ESCV presents three posters showcasing new data on NeuMoDx panels

    17 sept. 2019

    QIAGEN's Sajid Javed speaks about new data presented at the ESCV conference in Copenhagen on the performance of the CT/NG, EBV and HBV/HCV panels on the NeuMoDx system. He also highlights how the microfluidic cartridge simplifies molecular testing on the system. Go to: https://www.neumodx.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Benefits of Gel-free miRNA while working with large quantities of often challenging samples

    18 oct. 2019

    Daniel Kraushaar, Technical Director in the Genomic and RNA profiling core at Baylor College of Medicine discusses the benefits of gel-free miRNA while working with large quantities of often challenging samples. Learn more here: https://ashg.qiagen.com/rethink-rna-seq-to-uncover-elusive-transcriptomic-details/ Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Interview with Prof. Vincent Thibault on the benefits of the NeuMoDx system

    17 sept. 2019

    Prof. Vincent Thibault speaks at the ESCV Conference in Copenhagen on his results after testing the new NeuMoDx 96 system in his lab for infectious disease testing. Go to: https://www.neumodx.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Prof. Hubert Niesters speaks on "Point-of-Impact" vs. "Point-of-Care"

    18 sept. 2019

    Prof. Hubert Niesters of the University of Groningen speaks at ESCV in Copenhagen on the benefits and potential of syndromic testing, but also puts into perspective how "Point of Care" testing might currently be classified as "Point of Impact" instead. Go to: https://qiastat-dx.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Dr. Sehime Temel of the Department of Medical Genetics at Uludag University discusses BIOx

    21 oct. 2019

    Trying to find the appropriate genetic variant without bioinformatics is as impossible as “trying to find a single fish in the ocean”. Dr. Sehime Temel, of the Department of Medical Genetics at Uludag University in Turkey, explains how QCI Interpret is the magical tool that allows for diagnosis within a day rather than 6 months. Learn more: https://go.qiagen.com/NGSandanalysis Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Brandon Mistretta from the University of Houston discusses FastSelect at ASHG 2019

    21 oct. 2019

    FFPE based samples are just one form of challenging sample with often highly degraded DNA and RNA. Brandon Mistretta, doctoral student at the University of Houston’s Department of Biology and Biochemistry, discusses FastSelect RNA Extraction Kits in his immune-oncology research with samples previously thought unusable. Learn more: https://ashg.qiagen.com/rethink-rna-seq-to-uncover-elusive-transcriptomic-details/ Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • How to analyze RT² Profiler PCR Array and Assay data in GeneGlobe

    1 oct. 2019

    Learn how to analyze data from an RT² Profiler PCR Array using the GeneGlobe Analysis Center. Visit GeneGlobe to try it out yourself: https://geneglobe.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • The new QIAstat-Dx multiplex syndromic testing solution for infectious diseases

    5 nov. 2019

    See the new QIAstat-Dx syndromic testing platform in action. Easy to use, small footprint in a lab or point of care setting, First panels include respiratory infections. Find out more at http://qiastat-dx.com

  • RNeasy Plus Mini Kit – the faster way to pure RNA

    14 oct. 2019

    Learn about RNeasy Plus Kits for fast and convenient RNA extraction from cells or tissues, with effective removal of genomic DNA. Get high-quality total RNA in minutes using fast and easy-to-use extraction protocols and swap time spent on routine work for more important things.

  • Helping thousands of refugees and migrants dependent on fast and accurate latent TB results

    31 juil. 2019

    Amadou Gueye travels throughout Africa educating officials on the importance of standardizing TB testing knowing that prevention is key when it comes to stopping the spread of tuberculosis. Read the full story here: https://www.qiagen.com/de/insights-magazine/making-an-impact-in-africa About QuantiFERON-TB Gold Plus: https://www.quantiferon.com/products/quantiferon-tb-gold-plus-qft-plus/ Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Preethi Gunaratne of University of Houston discusses QIAcube and QIAGEN Extraction Kits

    18 oct. 2019

    The ultimate cancer treatment starts with sensing pre-cancerous tumors. Preethi Gunaratne, from the Department of Biology and Biochemistry at the University of Houston, uses the QIAcube Connect and QIAGEN’s gel-free extraction kits in her long-term goal of cancer prevention. QIAcube Connect Demo Tool: https://www.qiagen.com/media/product-tools/qiacube_connect-web/index.html Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • The challenges of generating high-quality RNA from human/bacterial samples simultaneously

    12 nov. 2019

    Dr. Marie Adams, Genomics Core Director at Van Andel Institute, discusses the challenges of generating high-quality RNA from human/bacterial samples simultaneously. Obtaining high-quality RNA from human/microbial samples for downstream RNA-seq applications can be challenging. Dr. Marie Adams discusses the use of the QIAseq FastSelect kit for simultaneous reduction of ribosomal RNA from human and bacterial samples to give high-quality mRNA for sequencing. Learn more at: https://go.qiagen.com/FastSelectCampaign Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Discover QIAGEN’s data analysis solutions

    4 déc. 2019

    QIAGEN offers Sample to Insight data analysis solutions for any requirements. Visit the GeneGlobe Data Analysis Center to learn more. https://geneglobe.qiagen.com/analyze/ Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Researchers standardize on AllTaq PCR in microbiology research

    26 juil. 2019

    At the University of Nottingham, these young scientists are working to find safe and effective therapies for Clostridium difficile associated diseases. C. diff microorganisms are responsible for some very serious and complex conditions, and this means their microbiology research involves a great deal of PCR in their daily experiments. For everyday PCR, our next-generation AllTaq Master Mix and PCR Core Kits provide an extremely robust and sensitive, hot-start PCR – using only one fast (45-minute) protocol, for all targets. The kits simplify PCR experiments and are very tolerant of variations in experimental conditions. Since using AllTaq, the Nottingham researchers are gaining better results, easier and faster, because AllTaq greatly simplifies the design of PCR experiments. Watch the video to learn about their research and how simplified PCR is helping their work. For more information about AllTaq PCR, see www.qiagen.com/alltaq-video

  • How to create a targeted DNA custom panel for NGS in GeneGlobe

    20 août 2019

    Learn how to create a QIAseq Targeted DNA Custom Panel for NGS using the GeneGlobe custom builders. Visit GeneGlobe to try it out yourself: https://geneglobe.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • How to analyze QIAseq Targeted DNA Panel data in GeneGlobe

    1 oct. 2019

    Learn how to analyze NGS data from a QIAseq Targeted DNA Panel using the GeneGlobe Analysis Center. Visit GeneGlobe to try it out yourself: https://geneglobe.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • A pathway to combat a bio-terrorist pathogen

    24 sept. 2019

    VEEV is classified as a bio-terrorist threat due to the aggressive onset of symptoms it’s aerosolized form is known for. A team of scientists from Virginia and Maryland are on a mission to find a therapeutic to stop the severe and debilitating disease caused by this arbovirus, using QIAGEN IPA software to unlock the pathways that trigger the innate immune response. Read the full story here: https://www.qiagen.com/insights-magazine/the-pathway-to-a-cure Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Lawrence Weiss, CSO at NeoGenomics Laboratories about PIK3CA

    23 juil. 2019

    At ASCO 2019, NeoGenomics Chief Science Officer Lawrence Weiss speaks about the PIK3CA gene and testing for it to treat for certain types of cancer. Recently FDA approved, the QIAGEN therascreen PIK3CA RGQ PCR kit is used at NeoGenomics Laboratories. It is a companion diagnostic for the breast cancer treatment PIQRAY from Novartis.

  • Peter Rene Hesse of QIAGEN discusses GeneGlobe

    18 oct. 2019

    GeneGlobe is the ultimate solution for the major dilemmas faced by all researches: time and budget. This web-based analysis platform lets users seamlessly navigate knowledge, products, and analyses relevant to their research within one streamlined tool. Visit: https://geneglobe.qiagen.com/ Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Booth tour: Sample to Insight solutions for molecular pathology at AMP 2019

    8 nov. 2019

    Find out what we have going on at the booth with QIAGEN’s Kimberly Dorans. Visit: amp.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Dr. Phil Febbo, Illumina, discusses the recent partnership between Illumina and QIAGEN

    27 nov. 2019

    Bringing NGS into clinical testing is challenging as customers need not only a trusted sequencing platform but also IVD content to cover the broad clinical testing needs of patients and healthcare providers. Illumina’s Chief Medical Officer, Phil Febbo, talks about a partnership between QIAGEN and Illumina that will address these needs and accelerate access to an expanded IVD menu for clinical NGS users. Read more: https://corporate.qiagen.com/newsroom/press-releases/2019/20191007_qiagen_illumina_ngs_collaboration Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Extracting seemingly impossible information from highly degraded touch DNA left on explosives

    18 nov. 2019

    Getting enough information from touch DNA on samples such weapons, explosives and degraded remains is incredibly challenging. Forensic scientists, like Dr. Sheree Hughes, are improving ways to get more genetic information from less sample to ultimately make communities safer and bring closure to families using QIAGEN DNA quantification kits. Read the full story here: https://www.qiagen.com/insights-magazine/explosive-discoveries Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • How to create a custom RT² PCR array in GeneGlobe

    3 sept. 2019

    Learn how to create a QIAseq Custom RT² PCR Array for mRNA or lncRNA using the GeneGlobe custom builders. Visit GeneGlobe to try it out yourself: https://geneglobe.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Peter Böhm and Nina Kjersgaard discuss why they chose dPCR for their research project

    21 oct. 2019

    Missing a single night of sleep may cause a shift in your genetic code. A research team from Rigshospitalet, Copenhagen decided to go with dPCR to ensure quality results in finding the circadian genes effected. Find out why. Learn more: https://go.qiagen.com/digital-PCR Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Dr. Rob Philibert discusses dPCR at ASHG 2019

    14 nov. 2019

    Dr. Rob Philibert explains the importance of digital PCR in clinical research. Learn more at: https://go.qiagen.com/digital-PCR

  • Thank you ESCV Copenhagen

    18 sept. 2019

    Here a quick overview and Wrap-Up of the QIAGEN Booth at ESCV Copenhagen 2019. See you in Manchester next year! Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • How QIAseq FastSelect helps pave the way towards more successful cancer treatment

    16 sept. 2019

    Two researchers are looking into novel ways to fight cancer from two different angles – using the body's own immune system and making the tumor microenvironment more hospitable to immune cells - with the help of FastSelect RNA removal kit to gain insights from challenging samples. Read the full story here: https://www.qiagen.com/insights-magazine/attacking-cancer-from-all-angles Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Meet us at AMP 2019 in Baltimore

    31 oct. 2019

    Learn more: https://amp.qiagen.com/ Corporate Workshops: https://amp.qiagen.com/qiagen-corporate-workshops/ Booth talk schedule: https://amp.qiagen.com/in-booth-talk-schedule/

  • Labcorp's Anjen Chenn speaks about FGFR molecular testing

    24 juil. 2019

    At ASCO 2019, LabCorp's Senior Director for Molecular Oncology Anjen Chenn, MD Ph.D, speaks about FGFR testing solutions from QIAGEN and how it works. He also answers the question: Why does Day One Lab Readiness matter?

  • Reducing time for clinical NGS test interpretation by 85%

    8 nov. 2019

    Ravindra Kolhe MD, PhD, Director of the Georgia Esoteric Molecular Laboratory at Augusta University and Peter Wild, PhD, Director of Senckenberg Institute for Pathology, University Hospital, Frankfurt, Germany Next-Generation Sequencing (NGS) is becoming widely used for biomarker detection in myeloid leukemia and lung cancer samples, allowing testing of multiple markers at the same time. We will explore how 2x pre-optimized assays on the QIAGEN NGS system have allowed laboratories to detect and call challenging variants in myeloid and lung cancer. The QIAGEN NGS System*, using the QIAact Myeloid DNA UMI panel and a custom lung cancer assay, offers a complete Sample to Insight solution including bioinformatics tailored and optimized for the panel’s analysis and reporting, using QCI Analyze and QCI Interpret. *The GeneReader NGS System is for research use only. Not for use in diagnostic procedures. Learn more: https://www.qiagenbioinformatics.com/qiagen-clinical-insight-analyze/ Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Join us at ESCV in Copenhagen

    4 sept. 2019

    Come visit our booth #12 at ESCV in Copenhagen and see what QIAstat-Dx and NeuMoDx can do to enhance your lab.

  • Syndromic solutions to aid therapeutic decision making for patients with respiratory infection

    12 nov. 2019

    In the clinical lab, acute conditions like respiratory disease require immediate intervention. Minutes count. Correct identification of the causative pathogen is key to selecting the right treatment, but many pathogens cause similar symptoms. Multiplex syndromic testing with the QIAstat-Dx, rapidly and simultaneously surveys a large number of pathogens, helping to eliminate the guesswork. These more accurate, comprehensive and actionable results allow your lab to provide clinicians with the information they need to confidently diagnose and guide therapy selection, improving patient care. Treating respiratory disease without a proper diagnosis can result in unnecessary prescribing of antibiotics, one of the driving forces for multidrug resistance in bacteria. Dr. Utsav Pandey from Children’s Hospital LA discusses the importance of syndromic testing to obtain an accurate diagnosis and treatment. Learn more about syndromic testing with the QIAstat-Dx: https://qiastat-dx.com/ Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • ESCV 2019 Booth Tour

    12 sept. 2019

    Come visit the QIAGEN Booth at the European Society for Clinical Virology Symposium in Copenhagen, Denmark, featuring the QIAstat-Dx syndromic testing solution and the NeuMoDx 96 high throughput PCR system.

  • ASHG 2019 Insights

    22 oct. 2019

    What brings all these great minds together to continue making advancements in human genetics and genomics?

  • Dr. Jean-Marc Senterre speaks about consolidating lab equipment

    18 sept. 2019

    Jean-Marc Senterre of CHR Citadelle Hospital in Liege, Belgium speaks about his search for the holy grail in the lab, consolidating high throughput with random access and LDT testing, and how after testing the NeuMoDx system the answer seems found.

  • The importance of a good bioinformatics pipeline for determining TMB score

    8 nov. 2019

    Tumor mutational burden is an important biomarker for immuno-oncology. Dr Ravindra Kolhe from the University of Augusta discusses the benefits of the QIAGEN Clinical Insight bioinformatics pipeline for calculating TMB score.

  • The importance of molecular testing to improve cancer patient outcomes - Dr. Allan Njau

    12 nov. 2019

    Dr. Allan Njau, Anatomical Pathologist at the Aga Khan University Hospital, Kenya, discusses the importance of molecular testing to improve cancer patient outcomes. Cancer incidence rates in Kenya are high and accompanied by elevated morbidity and mortality. Dr. Allan Njao discusses how molecular NGS testing paired with a comprehensive bioinformatics analysis and reporting pipeline, can help improve cancer patient outcomes. Learn more at: https://www.qiagenbioinformatics.com/products/qiagen-clinical-insight/ Learn more at: https://go.qiagen.com/FastSelectCampaign Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Defending the body against cancer by manipulating the immune system

    28 oct. 2019

    Nathalie Labarrier, a pioneer in the field of immuno-oncology, is working on revolutionizing cancer treatments with QIAseq Immune Repertoire and manipulating specific T-cells with ACT or anti-PD-1 in a new kind of cancer therapy. Read the story here: https://www.qiagen.com/insights-magazine/the-immune-system-as-medicine Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • AMP 2019 - Wrap up

    11 nov. 2019

    Thank you Baltimore, for a fantastic 25th anniversary AMP congress. Looking forward to another 25 years of AMP! See you next year. Learn more: amp.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Minimizing toxicities in cancer treatments with gut microbes

    18 nov. 2019

    The Microbiome has a profound impact on how patients react to various oncological treatments. Dr. Hannah Wardill’s explains how she uses QIAGEN DNA kits to research host-microbe interactions to come up with a personalized approach in medicine to minimize toxicities associated with the cancer therapies. Read the full story here: https://www.qiagen.com/insights-magazine/gut-microbiomes-as-a-cancer-therapy Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Get to know the GeneGlobe Design and Analysis Hub

    13 janv. 2020

    GeneGlobe streamlines the complete research cycle from target exploration, product configuration, data analysis and follow-up. Visit GeneGlobe to try it out yourself: https://geneglobe.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • ASHG 2019 Tip of the Day for Wednesday Oct. 16th

    17 oct. 2019

    Want to find out how to snag a GeneGlobe T-shirt? Maria Ramirez presents the QIAGEN Tips of the Day at #ASHG for Wednesday, October 16th. See you at booth #1119.

  • How to create a custom miRNA inhibitor in GeneGlobe

    20 nov. 2019

    Learn how to create a Custom miRCURY LNA miRNA Inhibitor using the GeneGlobe custom builders. Visit GeneGlobe to try it out yourself: https://geneglobe.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • ASHG19 - Wrap up

    21 oct. 2019

    #ASHG19 has been amazing. Hope you’ve enjoyed it as much as we have. You can still find out about our Sample to Insight solutions and see how they can transform your human genetics research: www.ashg.qiagen.com Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

  • Covance VP Thomas Turi on challenges with companion diagnostics

    23 juil. 2019

    At ASCO 2019, Tom Turi speaks about companion diagnostics and the benefits for labs and patients gained from the Day One Lab Readiness program from QIAGEN.

  • Meet us at ASHG 2019 in Houston

    17 oct. 2019

    Find QIAGEN at booth #1119 at the Annual ASHG Conference in Houston and see our DNA and RNA products, talk to our experts and learn more at @QIAGEN on Twitter

  • Testing millions to stop tuberculosis migration

    17 janv. 2020

    In the Gulf Region, labor migration is the main source of new Tuberculosis (TB) cases. Dr. Eskild Petersen, a world-renowned TB expert from Denmark, consults in Oman to spearhead the fight against the world's deadliest infectious disease. Go to: https://www.qiagen.com/insights-magazine/testing-millions-to-stop-tuberculosis-migration Subscribe to the QIAGEN YouTube channel: https://www.youtube.com/QIAGEN Follow us on: Twitter: https://twitter.com/QIAGEN Facebook: https://www.facebook.com/QIAGEN/ Linkedin: https://www.linkedin.com/company/8276/ Instagram: https://www.instagram.com/qiagen/

Entreprises - Essonne (91) - Les Ulis - R&D

Allez plus loin avec B-Reputation

Découvrez comment nos données peuvent répondre à vos besoins.

Veille stratégique

  • Fiches entreprises complètes
  • Alertes
  • Tableaux de bord
En savoir plus

Prospection

  • Fichiers de prospection sur mesure
  • 100 critères de segmentation
  • Adresses, mails et téléphones
En savoir plus

Enrichissement

  • Traitement de fichiers ou API
  • Siretisation et dédoublonnage
  • Information complète et indicateurs propriétaires
En savoir plus

Solution d'avis client

  • Collecte et vérification
  • Tableaux de bord d'analyse
  • Diffusion web et réseaux sociaux
En savoir plus